Latest aplastic anemia Stories
A comparison clinical study of two aplastic anemia treatments found that ATGAM, currently the only licensed aplastic anemia drug in the United States, improved blood cell counts and survival significantly more than did Thymoglobulin, a similar but reportedly more potent treatment.
Identifying a suitable donor for leukemia and lymphoma patients who need bone marrow transplants may be far easier now that results of two clinical trials show transplant results with half-matched bone marrow or umbilical cord blood are comparable to fully matched tissue, thanks in large part to the availability of effective antirejection drugs and special post-transplant chemotherapy.
Give Blood Now and Help a Neighbor This Season NEW YORK, Dec.
- Dr. Monica Bessler Launches New Center to Study, Treat Bone Marrow Failure - PHILADELPHIA, Oct. 4 /PRNewswire-USNewswire/ -- One of the world's leading experts in bone marrow failure and related blood disorders recently joined The Children's Hospital of Philadelphia.
Among patients receiving immunosuppressive therapy for severe aplastic anemia, a condition in which the bone marrow is unable to produce blood cells, the length of telomeres (chromosome markers of biological aging) was clearly associated with a higher rate of relapse and lower overall survival.
Although hematopoietic cell transplantation (HCT) cures many blood diseases, two-thirds of long-term survivors report at least one chronic health condition after the procedure.
Physicians may be able to safely lower the platelet dosage in transfusions for cancer and bone-marrow transplant patients without risking increased bleeding
CHESHIRE, Conn., Dec.
CHESHIRE, Conn., Dec. 8 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today reported positive results from AEGIS, an open-label registration study examining Soliris(R) (eculizumab) treatment of Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH).
- A morbid dread of being buried alive. Also spelled 'taphiphobia'.